Aethlon Medical (NASDAQ:AEMD) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Aethlon Medical (NASDAQ:AEMDGet Rating) in a research note issued on Friday. The brokerage set a “sell” rating on the medical equipment provider’s stock.

Separately, Maxim Group reduced their price target on shares of Aethlon Medical from $11.00 to $4.00 in a report on Tuesday, February 15th.

NASDAQ:AEMD opened at $0.89 on Friday. The stock has a market capitalization of $13.70 million, a price-to-earnings ratio of -1.48 and a beta of 0.81. The firm has a fifty day simple moving average of $1.26 and a two-hundred day simple moving average of $1.80. Aethlon Medical has a 12 month low of $0.88 and a 12 month high of $12.49.

Aethlon Medical (NASDAQ:AEMDGet Rating) last posted its quarterly earnings results on Monday, February 14th. The medical equipment provider reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.03). The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.26 million. Aethlon Medical had a negative return on equity of 45.91% and a negative net margin of 2,823.49%. During the same quarter in the previous year, the business posted ($0.20) earnings per share. On average, research analysts forecast that Aethlon Medical will post -0.58 EPS for the current year.

Several institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC lifted its stake in shares of Aethlon Medical by 377.0% in the fourth quarter. Renaissance Technologies LLC now owns 242,200 shares of the medical equipment provider’s stock valued at $450,000 after buying an additional 191,425 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Aethlon Medical by 20.9% in the fourth quarter. Geode Capital Management LLC now owns 164,952 shares of the medical equipment provider’s stock valued at $306,000 after buying an additional 28,501 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Aethlon Medical by 47.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 151,590 shares of the medical equipment provider’s stock valued at $282,000 after buying an additional 48,710 shares in the last quarter. BlackRock Inc. lifted its stake in shares of Aethlon Medical by 771.7% in the third quarter. BlackRock Inc. now owns 73,074 shares of the medical equipment provider’s stock valued at $282,000 after buying an additional 64,691 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new position in shares of Aethlon Medical in the third quarter valued at $111,000. 10.58% of the stock is currently owned by hedge funds and other institutional investors.

Aethlon Medical Company Profile (Get Rating)

Aethlon Medical, Inc, a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system.

See Also

Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.